Skip to main content

Table 1 Baseline characteristics of all patients

From: Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin

Variables N = 173
Age (range) 63.8 (25.0–84.0)
Sex (female / male) 86 (49.7%) / 87 (50.3%)
ECOG (0 / 1 / 2) 36 (20.8%) / 126 (72.8%) / 11 (6.4%)
BMI 23.0 ± 2.8
Charlson comorbidity index 8.0 ± 1.4
Stage (IIIB / IVA / IVB) 1 (0.6%) / 8 (4.6%) / 164 (94.8%)
Invasion
 Liver 47 (27.2%)
 Extrahepatic bile duct 26 (15.0%)
 Intestine 20 (11.6%)
 Peritoneum 2 (1.2%)
 Hepatic artery 15 (8.7%)
 Main portal vein 11 (6.4%)
Metastasis
 Liver 74 (42.8%)
 Peritoneum 46 (26.6%)
 Lung 29 (16.8%)
 Bone or muscular system 14 (8.1%)
 Distant lymph node 102 (59.0%)
Previous history
 Biliary drainage 49 (28.3%)
 Curative surgery 33 (19.1%)
 Palliative chemotherapy 12 (8.5%)
Baseline laboratory findings
 WBC (cells/μL) 6540.0 ± 5192.4
 CRP (mg/dL) 3.5 ± 4.0
 eGFR (mL/min/1.73m2) 92.8 ± 23.1
 AST (IU/L) 40.3 ± 40.3
 ALT (IU/L) 44.2 ± 50.8
 ALP (IU/L) 183.7 ± 174.9
 Bilirubin, total (mg/dL) 1.5 ± 2.4
 CEA (ng/mL) 68.6 ± 247.7
 CA 19–9 (U/mL) 2676.9 ± 6783.1
 NLR 4.2 ± 3.4
 PLR 189.0 ± 95.0
  1. ECOG Eastern Cooperative Oncology Group, BMI body mass index, WBC white blood cell, CRP C-reactive protein, eGFR estimated glomerluar filtration rate, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio